In the latest session, Cara Therapeutics Inc (NASDAQ: CARA) closed at $0.91 down -8.98% from its previous closing price of $1.00. In other words, the price has decreased by -$0.0898 from its previous closing price. On the day, 1226061 shares were traded.
Ratios:
For a deeper understanding of Cara Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.43 and its Current Ratio is at 4.54. In the meantime, Its Debt-to-Equity ratio is 0.76 whereas as Long-Term Debt/Eq ratio is at 0.76.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on March 08, 2023, Downgraded its rating to Underperform and sets its target price to $6 from $13 previously.
On March 08, 2022, JP Morgan Upgraded its rating to Overweight which previously was Neutral and also upped its target price recommendation from $17 to $20.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 29 when Posner Christopher sold 5,834 shares for $0.89 per share. The transaction valued at 5,192 led to the insider holds 180,521 shares of the business.
Goncalves Joana sold 3,293 shares of CARA for $2,931 on Feb 29. The CHIEF MEDICAL OFFICER now owns 56,118 shares after completing the transaction at $0.89 per share. On Feb 29, another insider, Terrillion Scott, who serves as the SEC’Y; CHIEF COMPLIANCE & G.C. of the company, sold 3,293 shares for $0.89 each. As a result, the insider received 2,931 and left with 91,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CARA now has a Market Capitalization of 49.58M and an Enterprise Value of -21.65M. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.36 while its Price-to-Book (P/B) ratio in mrq is 0.58. Its current Enterprise Value per Revenue stands at -1.02 whereas that against EBITDA is 0.18.
Stock Price History:
Over the past 52 weeks, CARA has reached a high of $10.28, while it has fallen to a 52-week low of $0.50. The 50-Day Moving Average of the stock is 0.6514, while the 200-Day Moving Average is calculated to be 1.8438.
Shares Statistics:
For the past three months, CARA has traded an average of 956.82K shares per day and 1.41M over the past ten days. A total of 53.80M shares are outstanding, with a floating share count of 46.25M. Insiders hold about 15.11% of the company’s shares, while institutions hold 47.00% stake in the company. Shares short for CARA as of Feb 15, 2024 were 2.23M with a Short Ratio of 2.33, compared to 2.38M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.10% and a Short% of Float of 5.72%.
Earnings Estimates
There are 5 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.42 for the current quarter, with a high estimate of -$0.33 and a low estimate of -$0.53, while EPS last year was -$0.49. The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.23 and low estimates of -$0.5.
Analysts are recommending an EPS of between -$1.09 and -$1.5 for the fiscal current year, implying an average EPS of -$1.25. EPS for the following year is -$0.94, with 5 analysts recommending between -$0.69 and -$1.08.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $2.35M this quarter.It ranges from a high estimate of $3.02M to a low estimate of $1.23M. As of the current estimate, Cara Therapeutics Inc’s year-ago sales were $6.17M, an estimated decrease of -61.90% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $1.44M, a decrease of -79.20% less than the figure of -$61.90% in the same quarter last year. There is a high estimate of $3.54M for the next quarter, whereas the lowest estimate is $80k.
A total of 5 analysts have provided revenue estimates for CARA’s current fiscal year. The highest revenue estimate was $13.66M, while the lowest revenue estimate was $1.98M, resulting in an average revenue estimate of $6.47M. In the same quarter a year ago, actual revenue was $20.97M, down -69.10% from the average estimate.
